Clinical Trials Logo

Clinical Trial Summary

CAR-T therapy is now available as a commercial product for treatment of relapsed /refractory acute lymphoblastic leukaemia and B-lymphoma. There is limited access to this new treatment as the product is very expensive. It is imperative to develop cost effective, closed circuit manufacturing systems for CAR-T cells to make CAR-T cells a point-of care production option. Hong Kong Institute of Biotechnology has established a certified GMP facility and utilize the Prodigy system to manufacture CAR-T cells for clinical application. Prince of Wales Hospital and Hong Kong Children's Hospital will conduct the phase II clinical trial to confirm the efficacy and safety of local manufactured CAR-T cell product.


Clinical Trial Description

This is a pilot study of CD19 specific CAR-T cells produced by the CliniMACS prodigy system in treatment of paediatric and adult with relapsed or refractory Acute Lymphoblastic Leukemia (ALL) or B cell Non-Hodgkin Lymphoma (NHL). Our study aims to evaluate the safety and effectiveness of CD19 specific CAR-T cells produced by a closed circuit, point of care, manufacturing system to develop safe and effective CD19 specific CART cells for treatment of relapsed B cell NHL and relapsed refractory B cell ALL in children and adults. The CliniMACS plus system of Miltenyi Biotec is an automated cell separator with proven clinical efficacy. The CliniMACS prodigy system has been successfully used to generate a CD19 CAR T using lentiviral transduction with good efficiency of transduction and the activity of the CAR T cells. This pilot study using anti-CD19 CAR-T cells generated by the CliniMACS prodigy system will be undertaken in the Prince of Wales Hospital under the Department of Clinical Oncology, Department of Medicine, and the Department of Anatomical & Cellular Pathology. Children will be managed at Hong Kong Children's Hospital. The subjects will comprise of paediatric and adult B cell ALL patients and cohort B of paediatric and adult B cell NHL patients. Eligible patients will go through Lymphapheresis procedures through central venous access. The cells will then be transferred to the CliniMACS prodigy system where they will be enriched and activated using the transAct CD3/CD28 Kit and transduced with a self-inactivating lentiviral vector encoding a CAR specific for CD19. The cells will be cultured, expanded and tested for efficiency of transduction, sterility and phenotype before preparation for patient use. The CAR-T cell treatment plan is consisted of a course of conditioning chemotherapy, followed by a single infusion of anti-CD19 CAR T cells after completion of conditioning / lymphodepletion chemotherapy. Patients will be observed as an inpatient for 7 days post treatment. Clinical status and progress of the patients, vital signs, blood counts, and blood chemistries will be monitored during and after CAR-T cell therapy. Occurrence of adverse events and serious adverse events will be recorded and managed with standard guidelines. Patients should be regularly followed up for at least two years after CAR T therapy. It is preferably to have long term follow-up of the patients beyond two years to look for any late complications ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06462248
Study type Interventional
Source Prince of Wales Hospital, Shatin, Hong Kong
Contact Chi Kong Li, MD
Phone 852-35051019
Email ckli@cuhk.edu.hk
Status Recruiting
Phase Phase 2
Start date June 1, 2024
Completion date December 31, 2027

See also
  Status Clinical Trial Phase
Completed NCT00270049 - Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia Phase 2
Completed NCT00452257 - A Study of Enzastaurin in Patients With Leukemia Phase 1
Completed NCT00313079 - Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia Phase 1
Completed NCT00327678 - Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Phase 3
Completed NCT00025662 - Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Phase 2
Terminated NCT00306332 - T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation Phase 3
Recruiting NCT05254743 - A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Phase 3
Completed NCT00034684 - Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) Phase 1/Phase 2
Completed NCT00361140 - Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Phase 4
Completed NCT00035022 - Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas Phase 1/Phase 2
Completed NCT01144793 - Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias N/A
Active, not recruiting NCT00315419 - Identifying Characteristics of Bone Marrow Failure Syndromes N/A
Active, not recruiting NCT03792256 - Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) Phase 1